Ballesteros, PA, García-Carbonero, I, Gonzalez, EE, Marin, AP, Lorente, D, de Liaño, AG, Ortega, EM, Colomo, LJ, Puente, J, Gonzalez, I, Calvo, OF, Palacios, GA, Mendizabal, I, Navarro, EP, Domínguez, JID, Esteban-Villarrubia, J, Billalabeitia, EG, Oria, GAD. Defining molecular correlates of response using spatial transcriptomics in the SOGUG-AUREA trial. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3696. PMID:. IF:65.400(Q1/1D).

España, MAG, Calle, SG, Flores, EG, Sosa, MM, Tocino, RV, Plazas, JG, Monteagudo, RF, Aguilera, MJS, Herrero, MDRM, Gargia, TG, Zafra, GM, Arévalo, MA, Orozco, EJ, Manrique, ACV, Alfonso, PG, Montes, AF, Ninerola, RQ, de Castro, EM, Verdaguer, H, García, RV. Characterization of locally advanced rectal cancer (LARC) patients (pt) in Spanish TTD-RETUD registry. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.1362. PMID:. IF:65.400(Q1/1D).

Kuboki, Y, Pietrantonio, F, Salvatore, L, Meriggi, FA, Modest, DP, Yaeger, R, Ruiz, E, Taieb, J, Karamouzis, MV, Esaki, T, Kim, TW, Cremolini, C, Strickler, JH, Masuishi, T, Paez, D, Chan, E, Chao, J, Tran, Q, Fakih, M, Hong, DS. Combined analysis of overall survival (OS) from the phase III CodeBreaK 300 and phase Ib CodeBreaK 101 studies of sotorasib 960 mg plus panitumumab (soto960+pani) therapy for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC). ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.1317. PMID:. IF:65.400(Q1/1D).

Ahrens, M, Haanen, JBAG, Albiges, L, Goupil, MG, Boleti, E, Gravis, G, Flechon, A, Grimm, MO, Bedke, J, Barthelemy, P, Gauna, DEC, Gonzalez, BM, Ivanyi, P, Rottey, S, Floercken, A, Rodriguez, CS, Rey, JPM, Burkholder, I, Hartmann, A, Bergmann, L. Exploratory analysis of chromophobe renal cell carcinoma in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first-line treatment. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3211. PMID:. IF:65.400(Q1/1D).

Sanborn, RE, Zhou, CC, Tang, KJ, Cho, BC, Cheng, S, Popat, S, Ono, A, Lu, S, Majem, M, Aguilar, A, Campelo, MDG, Hayashi, H, Lee, KY, Lee, SH, Delmonte, A, Alatorre-Alexander, J, Richardson, G, Santos, V, Dooms, C, Sabari, JK, Shu, CA, Girard, N, Mansfield, AS, Park, K, Xia, YC, Bhattacharya, A, Buyukkaramikli, N, Perualila, N, Diels, J, Acharya, S, Chandler, C, Proskorovsky, I, Dearden, L, Wortman-Vayn, H, Mahadevia, PJ, Knoblauch, RE, Agrawal, T, Baig, M, Felip, E. Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study. Targeted Oncology. 2025; 20(6)DOI:10.1007/s11523-025-01182-0. PMID:41184595. IF:4.000(Q2/3D).

Cardozo, AR, Kesselheim, A, Tibau, A. Magnitude of clinical benefit demonstrated in trials supporting FDA and EMA Approval of drugs for hematological malignancies, 2020-2024. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.1886. PMID:. IF:65.400(Q1/1D).

Muñoz-Couselo, E, Berciano-Guerrero, MA, Crespo, G, Castaño, AG, Manzano, JL, Miguel, PAD, Rosa, CA, Cerezuela-Fuentes, P, Puértolas, T, Sanz, LG, Medina, J, Cunquero-Tomás, A, Majem, M, Fernández, LA, Espinosa, E, Bellido, L, Soria, A, Bujosa, A, Algarra, SM, Marquez-Rodas, I. Real-world outcomes after immunotherapy discontinuation in advanced melanoma: Insights from the GEM1801 study. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.2263. PMID:. IF:65.400(Q1/1D).

Bergmann, L, Albiges, L, Ahrens, M, Goupil, MG, Boleti, E, Gravis, G, Flechon, A, Grimm, MO, Bedke, J, Barthelemy, P, Gauna, DEC, Gonzalez, BM, Ivanyi, P, Floercken, A, Rodriguez, CS, Rey, JPM, Gruenwald, V, Burkholder, I, Hartmann, A, Haanen, JBAG. Relevance of the CPS score and tumor nephrectomy in the SUNNIFORECAST trial comparing ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3216. PMID:. IF:65.400(Q1/1D).